Brain Cancer section

Brain Cancer News and Features

Prognostic Significance of Epidermal Growth Factor Receptor Expression in Glioma Patients

Prognostic Significance of Epidermal Growth Factor Receptor Expression in Glioma Patients

[OncoTargets and Therapy] A meta-analysis was conducted to evaluate the effect of abnormal EGFR expression on overall survival (OS) in patients with glioma.

Tumor-treating Fields Useful to Improve Glioblastoma Outcomes

Tumor-treating Fields Useful to Improve Glioblastoma Outcomes

Adverse event rates were similar in both trial groups, though patients treated with TTFields were much more likely to have mild to moderate skin toxicity.

History of Headache, Vomiting, Seizures Associated With Pediatric Brain Cancer

History of Headache, Vomiting, Seizures Associated With Pediatric Brain Cancer

Research pinpointed clinical factors, such as headache, that may be associated with pediatric brain neoplasms.

Drug Combination Does Not Extend Glioblastoma Survival

Drug Combination Does Not Extend Glioblastoma Survival

Lomustine plus bevacizumab may increase progression-free, but not overall, survival versus lomustine alone in progressive glioblastoma.

Invisible Burdens: The Complex Needs of Caregivers of Patients With Brain Cancer

Invisible Burdens: The Complex Needs of Caregivers of Patients With Brain Cancer

Caregivers of patients with malignant brain tumors often bear additional burdens in their role, as these patients often experience cognition-related adverse effects as well as the effects of their cancer and its treatment.

Brain Cancer Clinical Trials

Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma

With median age of participants in clinical trials for soft-tissue sarcoma younger than most patients who develop the disease, these researchers sought to determine the prevalence of including persons older than 65 in clinical trials and the efficacy of first-line chemotherapy for STS in older patients.

Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma

This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.

Determining Clinical Trial Eligibility

How is clinical trial eligibility determined?

Prognostic Significance of Epidermal Growth Factor Receptor Expression in Glioma Patients

[OncoTargets and Therapy] A meta-analysis was conducted to evaluate the effect of abnormal EGFR expression on overall survival (OS) in patients with glioma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs